{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:30:08Z","timestamp":1788881408318,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Research Foundation of Korea grant funded by the Korea government (MSIT)"},{"name":"the National Research Foundation of Korea grant funded by the Korea government (MSIT)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recommended antiviral drugs available for the treatment and prevention of influenza are neuraminidase inhibitors (NAIs). The aim of this study was to evaluate age-related clinical manifestations of adverse events (AEs) related to NAIs. FAERS and WebMD data were downloaded. The available NAIs selected for the analysis were oseltamivir, peramivir, zanamivir, and laninamivir. Disproportionality was analyzed using the proportional reporting ratio (PRR), the reporting odds ratio (ROR), and the information component (IC) methods. In total, 16729 AEs from 4598 patients and 575 AEs from 440 patients in the FAERS and WebMD, respectively, were included in the analysis. In the FAERS, AEs were more common among those who were younger (&lt;19 years) for zanamivir, while for those who were older (&gt;65 years) for peramivir. A disproportionality analysis showed that signals for vomiting and hallucinations were detected in younger patients given oseltamivir, while an abnormal hepatic function, cardiac failure, shock, and cardio-respiratory arrest were detected in older patients given peramivir. Psychiatric disorders were most common in younger and older patients, while gastrointestinal disorders were most common in adult given oseltamivir in the WebMD. Adverse symptoms related to NAIs varied and depended on the drugs used and the age of the patient.<\/jats:p>","DOI":"10.1038\/s41598-020-60068-5","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T11:03:17Z","timestamp":1582196597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews"],"prefix":"10.1038","volume":"10","author":[{"given":"Nayoung","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1836-1707","authenticated-orcid":false,"given":"Jung Mi","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Wha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"#cr-split#-60068_CR1.1","unstructured":"World Health Organization Influenza (Seasonal) Fact Sheet N. 211, https:\/\/www.who.int\/news-room\/detail\/11-03-2019-who-launches-new-global-influenza-strategy [(accessed on 13 July 2018)]"},{"key":"#cr-split#-60068_CR1.2","unstructured":"Available online, http:\/\/www.who.int\/mediacentre\/factsheets\/2003\/fs211\/en\/). (2019)."},{"key":"60068_CR2","unstructured":"Lindmeier, C. WHO launches new global influenza strategy, https:\/\/www.who.int\/news-room\/detail\/11-03-2019-who-launches-new-global-influenza-strategy. (2019)."},{"key":"60068_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/0253-7613.150308","volume":"47","author":"YK Gupta","year":"2015","unstructured":"Gupta, Y. K., Meenu, M. & Mohan, P. The Tamiflu fiasco and lessons learnt. Indian. J. Pharmacol. 47, 11\u201316 (2015).","journal-title":"Indian. J. Pharmacol."},{"key":"60068_CR4","doi-asserted-by":"publisher","first-page":"g2547","DOI":"10.1136\/bmj.g2547","volume":"348","author":"CJ Heneghan","year":"2014","unstructured":"Heneghan, C. J. et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348, g2547 (2014).","journal-title":"BMJ"},{"key":"60068_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fmicb.2016.00450","volume":"7","author":"MM Alame","year":"2016","unstructured":"Alame, M. M., Massaad, E. & Zaraket, H. Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections. Front. Microbiol. 7, 450 (2016).","journal-title":"Front. Microbiol."},{"key":"60068_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3349\/ymj.2017.58.4.778","volume":"58","author":"J Lee","year":"2017","unstructured":"Lee, J., Park, J. H., Jwa, H. & Kim, Y. H. Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis. Yonsei Med. J. 58, 778\u2013785 (2017).","journal-title":"Yonsei Med. J."},{"key":"60068_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4103\/0253-7613.103301","volume":"44","author":"N Tuna","year":"2012","unstructured":"Tuna, N., Karabay, O. & Yahyaoglu, M. Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatment. Indian. J. Pharmacol. 44, 780\u2013783 (2012).","journal-title":"Indian. J. Pharmacol."},{"key":"60068_CR8","unstructured":"Tamiflu (oseltamivir phosphate) capsules and for oral suspension [package insert] Nutley (NJ) Roche Laboratories Inc. 2008. [last cited 2010 May 28]. Available from, http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/InformationbyDrugClass\/UCM147992.pdf. (2019)."},{"key":"60068_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/pds.4721","volume":"28","author":"S Takeuchi","year":"2019","unstructured":"Takeuchi, S., Tetsuhashi, M. & Sato, D. Oseltamivir phosphate-Lifting the restriction on its use to treat teenagers with influenza in Japan. Pharmacoepidemiol. Drug. Saf. 28, 434\u2013436 (2019).","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"60068_CR10","unstructured":"Center for Infectious Disease Research and Policy CIDRAP. FDA panel: CHildren\u2019s deaths unrelated to Tamiflu, http:\/\/www.cidrap.umn.edu\/news-perspective\/2005\/11\/fda-panel-childrens-deaths-unrelated-tamiflu."},{"key":"60068_CR11","first-page":"43","volume":"9","author":"AB Shaik","year":"2018","unstructured":"Shaik, A. B., Prabhu, M., Shenoy, S. & Thomson, S. R. Oseltamivir-induced neuropsychiatric symptoms. J. Pharmacol. pharmacother. 9, 43\u201345 (2018).","journal-title":"J. Pharmacol. pharmacother."},{"key":"60068_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.neulet.2007.08.054","volume":"426","author":"Y Izumi","year":"2007","unstructured":"Izumi, Y. et al. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci. Lett. 426, 54\u201358 (2007).","journal-title":"Neurosci. Lett."},{"key":"60068_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4306\/pi.2010.7.4.302","volume":"7","author":"S Chung","year":"2010","unstructured":"Chung, S. & Joung, Y. S. Oseltamivir (tamiflu) induced depressive episode in a female adolescent. Psychiatry Investig. 7, 302\u2013304 (2010).","journal-title":"Psychiatry Investig."},{"key":"60068_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1176\/appi.ajp.2009.09101421","volume":"167","author":"LN Ho","year":"2010","unstructured":"Ho, L. N., Chung, J. P. & Choy, K. L. Oseltamivir-induced mania in a patient with H1N1. Am. J. Psychiatry 167, 350 (2010).","journal-title":"Am. J. Psychiatry"},{"key":"60068_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.9758\/cpn.2015.13.2.209","volume":"13","author":"SW Jeon","year":"2015","unstructured":"Jeon, S. W. & Han, C. Psychiatric Symptoms in a Patient with Influenza A (H1N1) Treated with Oseltamivir (Tamiflu): A Case Report. Clin. Psychopharmacol. Neurosci. 13, 209\u2013211 (2015).","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"60068_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0393-2","volume":"15","author":"K Morimoto","year":"2015","unstructured":"Morimoto, K. et al. Analysis of a child who developed abnormal neuropsychiatric symptoms after administration of oseltamivir: a case report. BMC Neurol. 15, 130 (2015).","journal-title":"BMC Neurol."},{"key":"60068_CR17","doi-asserted-by":"crossref","unstructured":"Matheson, N. J., Harnden, A. R., Perera, R., Sheikh, A. & Symmonds-Abrahams, M. Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev, CD002744 (2007).","DOI":"10.1002\/14651858.CD002744.pub2"},{"key":"60068_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-3827-4","volume":"19","author":"R Chen","year":"2019","unstructured":"Chen, R., Fang, Z. & Huang, Y. Neuropsychiatric events in an adult patient with influenza a (H3N2) treated with oseltamivir (Tamiflu): a case report. BMC Infect. Dis. 19, 224 (2019).","journal-title":"BMC Infect. Dis."},{"key":"60068_CR19","unstructured":"People 65 Years and Older & Influenza. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD) last reviewed: February 12, https:\/\/www.cdc.gov\/flu\/highrisk\/65over.htm (2019)."},{"key":"60068_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int. J. Med. Sci. 10, 796\u2013803 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"60068_CR21","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/pds.1459","volume":"16","author":"G Shalviri","year":"2007","unstructured":"Shalviri, G., Mohammad, K., Majdzadeh, R. & Gholami, K. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database. Pharmacoepidemiol. Drug. Saf. 16, 1136\u20131140 (2007).","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"60068_CR22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jbi.2011.07.005","volume":"44","author":"A Benton","year":"2011","unstructured":"Benton, A. et al. Identifying potential adverse effects using the web: a new approach to medical hypothesis generation. J. Biomed. Inf. 44, 989\u2013996 (2011).","journal-title":"J. Biomed. Inf."},{"key":"60068_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","volume":"157","author":"A Lackenby","year":"2018","unstructured":"Lackenby, A. et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017. Antivir. Res. 157, 38\u201346 (2018).","journal-title":"Antivir. Res."},{"key":"60068_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/ane.12629","volume":"135","author":"R Hama","year":"2017","unstructured":"Hama, R. & Bennett, C. L. The mechanisms of sudden-onset type adverse reactions to oseltamivir. Acta Neurol. Scand. 135, 148\u2013160 (2017).","journal-title":"Acta Neurol. Scand."},{"key":"60068_CR25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/23744235.2016.1189592","volume":"48","author":"R Hama","year":"2016","unstructured":"Hama, R. The mechanisms of delayed onset type adverse reactions to oseltamivir. Infect. Dis. 48, 651\u2013660 (2016).","journal-title":"Infect. Dis."},{"key":"60068_CR26","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1086\/651166","volume":"50","author":"K Nakamura","year":"2010","unstructured":"Nakamura, K., Schwartz, B. S., Lindegardh, N., Keh, C. & Guglielmo, B. J. Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin. Infect. Dis. 50, e47\u201349 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"60068_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/cr.2007.27","volume":"17","author":"CY Li","year":"2007","unstructured":"Li, C. Y. et al. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. Cell Res. 17, 357\u2013362 (2007).","journal-title":"Cell Res."},{"key":"60068_CR28","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/S0140-6736(98)10190-3","volume":"352","author":"Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections","year":"1998","unstructured":"Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 352, 1877\u20131881 (1998).","journal-title":"Lancet"},{"key":"60068_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3109\/00365548.2012.763104","volume":"45","author":"T Nakano","year":"2013","unstructured":"Nakano, T. et al. Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance. Scand. J. Infect. Dis. 45, 469\u2013477 (2013).","journal-title":"Scand. J. Infect. Dis."},{"key":"60068_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/cis351","volume":"55","author":"A Sorbello","year":"2012","unstructured":"Sorbello, A. et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin. Infect. Dis. 55, 1\u20137 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"60068_CR31","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","volume":"37","author":"C Michel","year":"2017","unstructured":"Michel, C., Scosyrev, E., Petrin, M. & Schmouder, R. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles? Clin. Drug. Investig. 37, 415\u2013422 (2017).","journal-title":"Clin. Drug. Investig."},{"key":"60068_CR32","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/irv.12598","volume":"12","author":"NM Cocoros","year":"2018","unstructured":"Cocoros, N. M. et al. Outpatient influenza antivirals in a distributed data network for influenza surveillance. Influenza Other Respir. Viruses 12, 804\u2013807 (2018).","journal-title":"Influenza Other Respir. Viruses"},{"key":"60068_CR33","doi-asserted-by":"crossref","unstructured":"Poluzzi, E., Raschi, E., Piccinni, C. & De Ponti, F. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). 266\u2013303 (InTech, 2013).","DOI":"10.5772\/50095"},{"key":"60068_CR34","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.cgh.2017.11.025","volume":"16","author":"V Chedid","year":"2018","unstructured":"Chedid, V., Vijayvargiya, P. & Camilleri, M. Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline. Clin. Gastroenterol. Hepatol. 16, 336\u2013338 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"60068_CR35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc, J. L., Sommet, A., Bagheri, H. & Lapeyre-Mestre, M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br. J. Clin. Pharmacol. 72, 905\u2013908 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"60068_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown, E. G., Wood, L. & Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug. Saf. 20, 109\u2013117 (1999).","journal-title":"Drug. Saf."},{"key":"60068_CR37","unstructured":"WebMD. WebMD Drugs & Medications - Medical information on prescription drugs, vitamins and over-the-counter medicines, http:\/\/www.webmd.com\/drugs\/index-drugs.aspx [accessed 2016-05-25]"},{"key":"60068_CR38","unstructured":"Beautiful Soup 4 Beautiful Soup Documentation - Beautiful Soup 4.4.0 documentation., [online] Available, https:\/\/www.crummy.com\/software\/BeautifulSoup\/bs4\/doc\/."},{"key":"60068_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug. Saf. 10, 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"60068_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug. Saf. 11, 3\u201310 (2002).","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"60068_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321 (1998).","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60068-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60068-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60068-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:18:03Z","timestamp":1670311083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60068-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60068"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60068-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]},"assertion":[{"value":"7 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3116"}}